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Recent data suggested an increased frequency of KIT aberrations in mucosal melanomas, whereas c-KIT in most types of cutaneous
melanomas does not appear to be of pathogenetic importance. However, studies investigating the status of the KIT gene in larger,
well-characterised groups of patients with mucosal melanomas are lacking. We analysed 44 archival specimens of 39 well-
characterised patients with mucosal melanomas of different locations. c-KIT protein expression was determined by
immunhistochemistry, KIT gene mutations were analysed by PCR amplification and DNA sequencing of exons 9, 11, 13, 17 and
18. c-KIT protein expression could be shown in 40 out of 44 (91%) tumours in at least 10% of tumour cells. DNA sequence analysis
of the KIT was successfully performed in 37 patients. In 6 out of 37 patients (16%) KIT mutations were found, five in exon 11 and one
in exon 18. The presence of mutations in exon 11 correlated with a significant stronger immunohistochemical expression of c-KIT
protein (P¼0.015). Among the six patients with mutations, in two patients the primary tumour was located in the head/neck region,
in three patients in the genitourinary tract and in one patient in the anal/rectal area. In conclusion, KIT mutations can be found in a
subset of patients with mucosal melanomas irrespective of the location of the primary tumour. Our data encourage therapeutic
attempts with tyrosine kinase inhibitors blocking c-KIT in these patients.
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Primary mucosal melanomas represent a rare subtype of
melanomas that arise from melanocytic cells residing in mucous
membranes in various anatomical regions. They account for
approximately 1.2% of melanomas (Chang et al, 1998) and have
mainly been described in the head and neck region, the
genitourinary tract and the gastrointestinal tract.
Obviously, sun exposure does not play a role in mucosal
melanoma, whereas it is a risk factor in cutaneous melanoma.
A recent study described genetic differences between mucosal
melanomas and cutaneous melanomas. In this study, four types of
melanomas were differentiated, that is, mucosal melanomas, acral
melanomas, melanomas on skin with chronic sun damage and
melanomas on skin without chronic sun damage. Melanomas
arising from skin without chronic sun damage, representing the
major group of cutaneous melanomas, were shown to frequently
harbour BRAF mutations, in particular the BRAF V600E mutation.
The other melanoma types, including mucosal melanoma, had a
high frequency of mutations of the KIT gene (Curtin et al, 2005,
2006). This finding is in particular intriguing as it may represent a
rationale for a targeted therapy with specific tyrosine kinase
inhibitors such as c-KIT blockers in mucosal melanomas. To
further elucidate the role of c-KIT and BRAF in mucosal
melanoma, we analysed these two targets in 39 patients with
mucosal melanomas treated in our Department.
MATERIALS AND METHODS
Patients
Thirty nine patients with mucosal melanomas who were treated in
our Department (Skin Cancer Center Hannover) from 1996 to 2007
were retrospectively analysed. A total of 44 archival formalin-fixed
and paraffin-embedded tissue samples (35 primary melanomas, 4
lymph node metastases, 2 skin metastases and 3 local recurrences)
were accessible for analysis in this study.
Immunohistopathologic evaluation of c-KIT expression
Highly sensitive immunohistochemistry for c-KIT with a murine
monoclonal antibody (clone p145, dilution 1:100, DakoCytoma-
tion, Hamburg, Germany) was performed as described earlier
(Satzger et al, 2008) and immunohistochemical stainings were
evaluated semiquantitatively. The numbers of positively labelled
melanoma cells were scored as follows: 0 for less than 10% positive
cells, 1 (þ) for 10–25% positive cells, 2 (þþ) for 26–50%
positive cells, 3 (þþþ) for 51–75% and 4 (þþþþ) for 76–
100% positive cells. We did not differentiate between
cytoplasmatic and membranous staining as we did not observe
isolated surface staining and earlier studies showed cytoplasmatic
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sstaining along with membranous staining in melanoma cells
positive for c-KIT (Pereira et al, 2005; Giehl et al, 2007; Rivera
et al, 2008).
Mutational analysis of KIT
Tumour cells were isolated from paraffin-embedded tissue (either
primary tumour, lymph node metastases, skin metastases or local
recurrences), if necessary by micrographic dissection using
the PALM Laser-MicroBeam System (PALM Wolfratshausen,
Germany). DNA extraction was performed with the DNA extraction
kit from Qiagen (Hilden, Germany) following the instructions of
the manufacturer. Exons 9, 11, 13, 17, 18 of KIT were amplified by
LightCycler PCR using specific primers as described in the
literature (Tarn et al, 2005; Curtin et al, 2006). Polymerase chain
reaction products were DNA sequenced using an ABI Prism 3700
DNA Analyzer (SeqLab, Go ¨ttingen, Germany).
Mutational analysis of BRAF
To detect the BRAF V600E mutation a LightCycler fluorescence
resonance energy transfer (FRET) assay with two fluorescent
hybridisation probes was performed as described earlier (Hay
et al, 2007). Real-time PCR was performed by using LightCycler
FastStart DNA Master HybProbe (Roche Diagnostics GmbH,
Mannheim, Germany). Post amplification fluorescent melting
curve analysis was performed by gradual heating of the samples
at a rate of 0.21C per second from 45 to 951C. Fluorescent melting
peaks were determined by plotting of the negative derivative of
fluorescence with respect to temperature.
All PCR products that showed deviation from the Wt (wild-type)
genomic DNA melting peak as well as from the positive control
samples were confirmed by direct sequencing of exon 15 of the
BRAF gene (SequiServe, Vaterstetten, Germany).
Statistical analyses
The software SPSS 13.0 was used for statistical analyses. Kaplan–
Meier tests and unpaired t-tests were performed.
RESULTS
c-KIT expression was determined in 44 tissue samples, 35 primary
mucosal melanomas, 4 lymph node metastases, 2 skin metastases
and 3 local recurrences (Table 1). In all, 31 out of 35 (89%)
primaries, 4 out of 4 (100%) lymph node metastases, 2 out of 2
(100%) skin metastases and 3 out of 3 (100%) local recurrences
were positive for c-KIT (Figure 1A). c-KIT protein expression
could be detected in 18 out of 18 (100%) mucosal melanomas
located in the head/neck area, 7 out of 8 (86%) in the anal/rectal
tract, 8 out of 11 (73%) in the genitourinary tract and 2 out of 2
(100%) in other locations. Score 1þ was determined in 8 out of 44
samples (18%), score 2þ in 7 out of 44 (16%) samples, score 3þ
in 9 out of 44 (20%) samples and score 4þ in 16 out of 44 samples
(36%). The degree of the c-KIT expression did not correlate with
disease-free survival (P¼0.44) and overall survival (P¼0.82) by
Kaplan–Meier analysis during a follow-up of 31.1 months (mean)
and 21.1 months (median, minimum 2.8 months, maximum 151.6
months). During that follow-up period, 20 patients suffered from
melanoma recurrence and 14 patients died due to melanoma
metastases.
Alterations in the KIT gene were observed in 6 out of 37 (16%)
patients, five in exon 11 and one in exon 18 (Figure 1B). Two
patients suffered from mucosal melanomas of the head/neck
region, three patients from mucosal melanomas located in the
genitourinary tract and one patient from mucosal melanoma
located in the anal/rectal tract. In one patient (case 27) the KIT
mutation could be detected both in lymph node metastases and in
skin metastases. Among the five tumours with KIT gene mutation
of exon 11, four (80%) tumours showed strong (þþþþ) and
one showed (20%) high (þþþ) c-KIT protein expression
(Figure 1A). In contrast, tumours without mutation in exon 11
had significantly lower c-KIT expression (3 out of 32 negative, 7
out of 32 (þ), 7 out of 32 (þþ), 8 out of 32 (þþþ), 7 out of 32
(þþþþ), P¼0.015).
In 3 out of 27 (11%) mucosal melanomas (located in head/neck
area, pleura and conjunctiva, respectively) the BRAF V600E
mutation could be detected (Table 1, Figure 1C).
DISCUSSION
A recent report showed a possible role of c-KIT in subsets of
melanoma, in particular, mucosal melanomas (21% KIT mutations,
61% c-KIT overexpression), acral cutaneous melanomas (11% KIT
mutations, 75% c-KIT overexpression) and cutaneous melanomas
on skin with chronic sun damage (17% KIT mutations, 100% c-KIT
overexpression) (Curtin et al, 2006). This suggests that c-KIT
might be of pathogenetic relevance and therefore a therapeutic
target in these subtypes of melanoma. In contrast, KIT mutations
are rarely found in the major subtype of cutaneous melanoma
originating from skin without chronic sun damage (Curtin et al,
2006) and unselected cutaneous melanomas (2 out of 100 in
Willmore-Payne et al (2005); 1 out of 39 in Went et al (2004)).
Moreover, therapeutic phase II studies with the c-KIT blocker
imatinib in unselected melanoma patients without known KIT
mutation status were disappointing (Ugurel et al, 2005; Wyman
et al, 2006; Becker et al, 2007).
The aim of this study was to further elucidate c-KIT alterations
in our well-characterised group of patients with mucosal
melanomas that might support the role of c-KIT as a new
therapeutic target in this subgroup of melanoma. The successful
genetic analysis of KIT in 37 patients revealed mutations in 6
patients (16%). We could show KIT mutations in 2 out of 12
mucosal melanomas from head/neck, 3 out of 11 from the
genitourinary tract and 1 out of 8 from the anal/rectal tract.
This is consistent with the findings of Antonescu et al and
Rivera et al who detected mutations of the KIT gene in 3 out of 20
(15%) and 4 out of 18 (22%) patients with mucosal melanomas of
the anal region and oral cavity, respectively (Antonescu et al, 2007;
Rivera et al, 2008). Thus, KIT mutations occur in up to 20% of
mucosal melanomas irrespective of the location of the primary
tumour.
The majority of KIT mutations in mucosal melanomas (11 out
of 16 tumours in Curtin et al (2006), 3 out of 3 in Antonescu
et al (2007), 4 out of 4 in Rivera et al (2008) and 5 out of 6 in
our study) were detected in the juxtamembrane region of KIT
encoded by exons 11 and 13, presumably resulting in the activation
of c-KIT.
The L576P und W557R mutations of our patients have already
been described both in mucosal melanomas and gastrointestinal
stromal tumours (GIST) (Antonescu et al, 2004, 2007; Rivera et al,
2008). Deletions covering the 579 position (such as in our patient
24) have also been frequently described in GIST (Tarn et al, 2005).
The K550N mutation found in our patient 2 has, to our knowledge,
not been described yet. However, other alterations in the proximal
part of exon 11 at codons 550–562 have been reported frequently
in GIST (Lasota et al, 1999; Longley et al, 2001).
Thus, the minor subgroup of patients with mucosal melanomas
and activating KIT mutations might be susceptible to therapeutic
c-KIT blockade. This is supported by findings in GIST, which show
KIT mutations in 75–80%, and respond significantly better to a
therapy with the c-KIT inhibitor imatinib than tumours without
KIT mutations (Heinrich et al, 2003). Therefore, therapeutic c-KIT
blockade could be considered for the treatment of patients with
c-KIT in melanoma
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smucosal melanomas and an activating KIT mutation. This is
supported by two case reports published very recently of single
patients suffering from metastasising anal melanoma that
harboured a KIT mutation in exon 11 and exon 13, respectively.
These patients were successfully treated with the c-KIT blocker
imatinib (Hodi et al, 2008; Lutzky et al, 2008).
c-KIT protein expression could be observed in 91% of our
primary mucosal melanomas, which is similar to the rates reported
in other series of primary mucosal melanomas of the anal/rectal
tract (12 out of 16 in Chute et al, 2006) and oral cavity (16 out of 18
in Rivera et al, 2008), respectively. However, Antonescu et al
(2007) reported lower number (6 out of 26 (23%)) of c-KIT
positivity in mucosal melanomas of the anal/rectal tract.
In addition, cutaneous melanomas have been reported to express
c-KIT by immunohistochemistry in 22.8% (Potti et al, 2003) up to
84% (Giehl et al, 2007) of the cases. The high range between these
studies is being explained with the different qualities of
immunohistochemistry. Thus, c-KIT protein expression appears
to be in a similar range in mucosal melanomas and cutaneous
melanomas. In line with this, Giehl et al could find no differences
of the c-KIT expression in melanomas with sun exposure
compared with melanomas without sun exposure (Giehl et al,
2007). In contrast to metastatic melanoma from primary cutaneous
melanoma, where the c-KIT expression is decreased (Montone
et al, 1997; Shen et al, 2003), we could observe c-KIT expression in
9 out of 9 metastases of primary mucosal melanoma. Similarly,
Antonescu et al detected c-KIT reactivity in 6 out of 6 metastases
from their anal mucosal melanomas (Antonescu et al, 2007).
Furthermore, in agreement with earlier studies we could not show
a prognostic relevance of the c-KIT protein expression in mucosal
melanomas (Chute et al, 2006).
We could observe a significant higher immunohistochemical
expression of c-KIT in mucosal melanomas that harbour a
potentially activating KIT mutation as compared with tumours
Table 1 Characterisation of patients, expression of c-KIT by immunohistochemistry (IHC), mutational status of KIT and BRAF in mucosal melanoma,
clinical follow-up
Case
Age
(years) Gender Location Tissue sample IHC c-KIT KIT status
BRAF
status Follow-up
1 80 F Head/Neck PM ++++ Wt Wt Progression in 9 months
2 44 M Head/Neck PM +++ Exon 11, K550N Wt Progression in 5 months
3 69 F Head/Neck PM + NA Wt Death due to melanoma in 74 months
LN ++ Wt Wt
4 75 M Head/Neck PM +++ Wt Wt Death due to melanoma in 8 months
5 52 M Head/Neck PM +++ Wt NA No progression
6 75 M Head/Neck PM +++ Wt Wt Progression in 27 months
7 59 M Head/Neck PM ++++ NA NA Progression in 8 months
LR ++++ Wt Wt
8 77 M Head/Neck LR + Wt NA Progression in 24 months
9 80 F Head/Neck PM ++++ Wt Wt No progression
10 64 M Head/Neck PM ++++ Wt Wt No progression
11 68 F Head/Neck PM +++ Wt NA Death due to melanoma in 11 months
12 72 M Head/Neck PM ++ Wt Wt Death due to melanoma in 25 months
13 78 M Head/Neck PM ++++ Wt Wt Progression in 11 months
14 94 M Head/Neck PM ++++ Exon 11,
W557R
Wt Death due to melanoma in 7 months
15 63 F Head/Neck PM ++ Wt Wt Death due to melanoma in 5 months
16 57 M Head/Neck PM + Wt hetero Death due to melanoma in 6 months
17 59 M Head/Neck PM +++ Wt Wt No progression
18 80 F Head/Neck PM + Wt Wt No progression
19 22 F Genital tract PM negative NA NA No progression
20 59 F Genital tract PM + Wt NA Progression in 33 months
21 72 F Genital tract PM ++++ Wt NA No progression
22 65 F Genital tract PM +++ Wt Wt Death due to melanoma in 32 months
23 86 F Genital tract PM negative Wt Wt NA
24 65 F Genital tract PM ++++ Exon 11,
579del
Wt No progression
25 50 F Genital tract PM ++ Exon 18, I841V Wt No progression
26 81 F Genital tract PM negative Wt NA Death due to melanoma in 37 months
27 76 F Genital tract PM ++++ NA NA Death due to melanoma in 13 months
SM ++++ Exon 11, L576P NA
LN ++++ Exon 11, L576P NA
28 65 F Genital tract LR +++ Wt Wt Death due to melanoma in 11 months
29 74 F Urinary tract PM ++++ NA Wt Death due to melanoma in 114 months
30 61 M Anal/rectal PM ++++ Wt NA Death due to melanoma in 51 months
31 65 M Anal/rectal PM negative Wt NA Death due to melanoma in 25 months
32 65 F Anal/rectal PM +++ Wt Wt Death due to melanoma in 16 months
33 73 M Anal/rectal PM ++ Wt Wt Progression in 13 months
SM ++++ Wt Wt
34 66 M Anal/rectal PM + Wt Wt Death due to melanoma in 24 months
35 55 M Anal/rectal LN ++ Wt NA Progression in 26 months
36 79 F Anal/rectal PM ++++ Exon 11, L576P Wt Progression in 9 months
37 64 F Anal/rectal PM + Wt NA Distant metastasis at diagnosis
38 52 F Conjunctiva LN + Wt hetero Death due to melanoma in 137 months
39 53 F Pleura PM ++ Wt hetero Progression in 3 months
hetero¼heterozygous, LN¼lymph node metastasis; LR¼local recurrence, NA¼not available, PM¼primary melanoma, SM¼skin metastasis, Wt¼wild-type. IHC-
assessment: negative for less than 10% positive cells, +for 10–25% positive cells, ++ for 25–50% positive cells, +++ for 50–75% and ++++ for 75 to 100% positive cells.
c-KIT in melanoma
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swithout KIT mutation. A similar correlation has also been found
for anal melanomas (Antonescu et al, 2007) and melanomas of the
oral cavity (Rivera et al, 2008).
Thus, immunohistochemistry might be a useful tool to screen
for patients that are subjected to KIT mutation analysis. However,
immunohistochemistry might not be sufficient to detect tumours
with mutations susceptible for c-KIT blockade, as overexpression
of c-KIT can also occur in tumours without mutation. This is
illustrated by the report of three patients with metastatic
melanoma and strong immunohistochemical c-KIT expression
who did not respond to a therapy with the c-KIT blocker imatinib
(Alexis et al, 2005).
BRAF mutations were rarely identified in 3 out of 27 (11%)
patients in our series, similarly to other studies with patients
suffering from mucosal melanomas who reported 1 out of 17
(Cohen et al, 2004) and 0 out of 13 (Edwards et al, 2004),
respectively, whereas the majority of cutaneous melanomas on
skin without chronic sun-induced damage harbour BRAF V600E
mutations (Curtin et al, 2005). It is interesting to note that one of
our patients with a BRAF mutation suffered from melanoma
located in an UV-exposed area of the conjunctiva. In line with this,
Gear et al (2004) reported BRAF mutations in 5 out of 22 patients
with conjunctival melanomas.
In conclusion, our study supports the finding that KIT
mutations presumably activating the tyrosine kinase activity of
c-KIT can be found in a subgroup of patients with mucosal
melanomas irrespective of the origin of the primary tumour. This
encourages clinical studies with c-KIT blockers in patients with
mucosal melanomas and appropriate KIT mutations. Immunohis-
tochemistry for c-KIT expression might be a useful tool to screen
for patients who are subjected to mutational analysis but cannot
replace genetic analysis.
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